Role of chemokine RANTES in the regulation of perivascular inflammation, T-cell accumulation, and vascular dysfunction in hypertension.
about
Novel adaptive and innate immunity targets in hypertension.A salt-sensing kinase in T lymphocytes, SGK1, drives hypertension and hypertensive end-organ damageNovel Immune Mechanisms in Hypertension and Cardiovascular Risk.The role of infiltrating immune cells in dysfunctional adipose tissue.The role of chemokines in hypertension and consequent target organ damage.Perivascular adipose tissue: epiphenomenon or local risk factor?Perivascular adipose tissue inflammation in vascular disease.Protease-Activated Receptor 1 Contributes to Angiotensin II-Induced Cardiovascular Remodeling and Inflammation.Pro-contractile effects of perivascular fat in health and disease.Cytotoxic lymphocytes and atherosclerosis: significance, mechanisms and therapeutic challenges.Role of the Immune System in Hypertension.C-C Motif Chemokine 5 Attenuates Angiotensin II-Dependent Kidney Injury by Limiting Renal Macrophage Infiltration.Serum Cytokines in Young Pediatric Patients with Congenital Cardiac Shunts and Altered Pulmonary Hemodynamics.Perivascular Adipose Tissue Harbors Atheroprotective IgM-Producing B Cells.The immunology of hypertension.Macrophages come to mind as keys to cognitive decline.Anti-atherosclerotic effect of the angiotensin 1-7 mimetic AVE0991 is mediated by inhibition of perivascular and plaque inflammation in early atherosclerosis.Genetic Interference With Endothelial PPAR-γ (Peroxisome Proliferator-Activated Receptor-γ) Augments Effects of Angiotensin II While Impairing Responses to Angiotensin 1-7.Epigenetics and Immunometabolism in Diabetes and Aging.Aortic dysfunction in metabolic syndrome mediated by perivascular adipose tissue TNFα and NOX2 dependent pathway.Heterogenous treatment effects: secrets for a reliable treat-to-target trial?Perivascular Adipose Tissue as a Relevant Fat Depot for Cardiovascular Risk in Obesity.Microvascular dysfunction in ankylosing spondylitis is associated with disease activity and is improved by anti-TNF treatment
P2860
Q30235116-0F135B46-16AE-48D3-9268-3744D8E99031Q33877762-FF64C991-7A37-4B73-B2A1-777888DD9F1AQ37683209-FEEF08D8-1465-4B32-8B09-AC0883992C85Q38637700-5CE7E27C-AAF0-451C-A6BF-992DC7B6080EQ38747937-809B0B07-15E1-4ABA-B0AE-55AEDA9D7770Q38772223-8B3E0EBE-8179-49FE-AB9F-6CC4020DDD25Q39072710-C55C3268-11AB-4006-BA4A-FB78863BAF66Q39158447-306B412A-AFEE-4C00-8A08-365CE7952580Q39159968-55385C9D-BBD2-4EBC-AFA4-5FEC1F2D7063Q39283173-B901346D-5325-42A8-B3CE-3BBC8623FABDQ39342382-BB1533B5-348D-4986-8C8F-23A2F23A9435Q39377637-46B48B8A-E116-4C40-A67F-5CC15A2A00D3Q41079973-C7D51ADE-33C1-4126-B191-E08BF969BF6AQ41899674-E499B68A-3B4C-443F-9F91-DD6831C3CD83Q46238640-04FE3D99-286E-418C-9160-CF40511218F5Q46423522-5F9E204F-4772-4206-BB9B-ED9766A97D2AQ47104825-3E86B0EF-F1C5-4A42-9406-016E300AE341Q47710820-A9C9C72D-727D-44FA-AD4D-0655278EEA72Q47955532-32A6CE42-9B96-45EC-9AA9-F3A389B6185AQ48211716-755294CE-6048-4FB1-A1D4-7DA66E471FADQ54980602-28558314-7D28-42B1-B628-533C94828E37Q55122068-179DF3B7-C98E-4BF0-9F24-F9D647A02CE2Q58765329-DF45DE88-5130-42E2-B072-DA5928576030
P2860
Role of chemokine RANTES in the regulation of perivascular inflammation, T-cell accumulation, and vascular dysfunction in hypertension.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Role of chemokine RANTES in th ...... r dysfunction in hypertension.
@ast
Role of chemokine RANTES in th ...... r dysfunction in hypertension.
@en
type
label
Role of chemokine RANTES in th ...... r dysfunction in hypertension.
@ast
Role of chemokine RANTES in th ...... r dysfunction in hypertension.
@en
prefLabel
Role of chemokine RANTES in th ...... r dysfunction in hypertension.
@ast
Role of chemokine RANTES in th ...... r dysfunction in hypertension.
@en
P2093
P2860
P50
P356
P1433
P1476
Role of chemokine RANTES in th ...... ar dysfunction in hypertension
@en
P2093
Agnieszka Sagan
Bartlomiej Guzik
David G Harrison
Grzegorz Osmenda
Heinrich E Lob
Jakub Podolec
Klaudia Budzyn
Paul J Marvar
Piotr Szczepaniak
Ryszard Nosalski
P2860
P304
P356
10.1096/FJ.201500088R
P407
P577
2016-02-12T00:00:00Z